Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effectiveness and Safety of Allergenic Extract of Olea Europaea Pollen for Patients with Moderate-to-Severe Olive Pollen Allergy

Registered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a treatment for people who have been suffering from moderate-to-severe allergic rhinitis or rhinoconjunctivitis due to olive pollen for at least two years. The treatment being tested is called CLU-RX-OLE, which is a type of immunotherapy given through injections. The study aims to find the most effective and well-tolerated dose of this treatment. Participants in the study will receive either the CLU-RX-OLE treatment or a placebo, which looks like the treatment but does not contain the active ingredient.

During the study, participants will be monitored to see how their symptoms change over time. The study will compare the symptoms and medication use of those receiving the active treatment with those receiving the placebo. This will help determine the treatment's effectiveness in reducing symptoms and improving the quality of life for those with olive pollen allergies. The study will also assess the safety and any side effects of the treatment.

The trial will take place over a period of time, with participants being asked to keep track of their symptoms and any medications they use. This information will be used to evaluate the treatment's impact on their condition. The goal is to find a balance between the benefits and any potential risks of the treatment, ensuring it is both effective and safe for patients with olive pollen allergies.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying a history of moderate-to-severe allergic rhinitis or rhinoconjunctivitis due to olive pollen for at least two years.

    A skin prick test is performed to confirm sensitization to Olea europaea pollen. A positive result is indicated by a wheal diameter of at least 3 mm.

  2. Step 2

    Baseline evaluation

    A baseline evaluation is conducted to establish initial health parameters. This includes completing an electronic diary for self-evaluation of symptoms and rescue medication use.

    Safety laboratory tests are performed to ensure results are within normal ranges or not clinically significant.

  3. Step 3

    Treatment phase

    The treatment phase involves subcutaneous cluster-immunotherapy with CLU-RX-OLE, which is an allergenic extract of Olea europaea pollen.

    The treatment is administered through injections, with doses adjusted to determine the most effective and best-tolerated dose.

  4. Step 4

    Medication administration

    During the trial, medications such as mometasone furoate nasal spray and loratadine tablets may be used to manage symptoms.

    Mometasone furoate is administered as a nasal spray, while loratadine is taken orally in tablet form.

  5. Step 5

    Monitoring and evaluation

    Throughout the trial, symptoms and medication use are monitored using the electronic diary.

    Regular assessments are conducted to evaluate the efficacy and safety of the treatment, including the Combined Symptom and Medication Score (CSMS) during the peak olive pollen period.

  6. Step 6

    Final assessment

    At the end of the trial, a final assessment is conducted to evaluate the overall effectiveness and safety of the treatment.

    The results are compared to the baseline evaluation to determine any improvements in symptoms and quality of life.

Who can join the trial?

7 criteria

  • Patients must have signed and dated the informed consent form before any study-specific examination.
  • Participants can be female or male and must be between 18 and 65 years old at the time of signing the informed consent form.
  • Patients should have had moderate-to-severe allergic rhinitis (a condition causing sneezing, stuffy or runny nose) or rhinoconjunctivitis (similar symptoms affecting the eyes) due to olive pollen for at least two years. This should be according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline. They can have mild-to-moderate asthma that is well-controlled or no asthma at all.
  • For patients with asthma, their forced expiratory volume (FEV1) in one second should be more than 80% of the predicted normal value. FEV1 is a measure of how much air a person can forcefully exhale in one second.
  • Patients must be sensitized to Olea europaea pollen, which means they have an allergic reaction to it. This is verified by a positive skin prick test and a specific blood test showing a certain level of allergy antibodies (IgE) to Olea europaea. They should also have a certain score on a symptom scale based on their worst days in the past and a positive response to a nasal test with olive pollen or a similar allergen.
  • Patients must be able to understand and use an electronic diary to record their symptoms and any medication they take. They should be able to follow the instructions given by the study staff.
  • Laboratory test results should be within the normal range or not considered to be of clinical concern.

Who cannot join the trial?

4 criteria

  • Patients who have not experienced moderate-to-severe allergic reactions to olive pollen for at least two years.
  • Patients who do not meet the guidelines for allergic rhinitis or rhinoconjunctivitis, which are conditions involving inflammation of the nose and eyes due to allergies.
  • Patients who are not within the specified age range for the study.
  • Patients who are part of a vulnerable population, meaning they may need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

CLUSTOID®/CLUXIN® Olea europaea is a type of immunotherapy used in this clinical trial. It is designed to help patients who are allergic to Olea europaea pollen, commonly known as olive tree pollen. The therapy involves administering the treatment under the skin in a series of doses. The goal is to gradually increase the patient's tolerance to the pollen, reducing allergic symptoms and the need for other allergy medications. This study aims to find the most effective and well-tolerated dose for patients, balancing the benefits and any potential risks.

What is already known about the treatment

CLUSTOID®/CLUXIN® Olea europaea – This medication is administered subcutaneously, meaning it is injected under the skin. It is currently being studied in clinical trials to determine its effectiveness and safety for treating moderate-to-severe allergic rhinitis or rhinoconjunctivitis caused by olive pollen. The main therapeutic indication is to alleviate symptoms associated with these allergic conditions. The medication works by gradually desensitizing the immune system to olive pollen, reducing allergic reactions over time. It is classified as an immunotherapy agent, specifically designed to modify the body's immune response to allergens.

Investigated diseases

Allergic Rhinitis – Allergic rhinitis is a condition characterized by inflammation of the nasal passages due to an allergic reaction. It is often triggered by allergens such as pollen, dust, or pet dander. Symptoms include sneezing, runny or stuffy nose, itchy eyes, and throat. The condition can be seasonal, as in hay fever, or perennial, occurring year-round. Over time, exposure to allergens can lead to persistent symptoms and discomfort. The severity of symptoms can vary, with some individuals experiencing mild irritation and others facing more significant disruption to daily activities.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IVTrial ID2024-511383-88-00Protocol codeSC-3C2AEstimated enrolment560 patientsSponsorROXALL Medizin GmbH

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.